Drug repurposing for Basal breast cancer subpopulations using modular network signatures

• Published in: Computational biology and chemistry 2023-08, Vol.105, p.107902-107902, Article 107902
• Main Authors: Coria-Rodríguez, Hiram, Ochoa, Soledad, de Anda-Jáuregui, Guillermo, Hernández-Lemus, Enrique
• Format: Article
• Language: English
• Subjects: Basal breast cancer; Drug Repositioning; Drug repurposing; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Modular network signatures; MultiOmic regulation; Neoplasms; Perturbation assays; Transcriptome
• ISSN: 1476-9271; 1476-928X
• DOI: 10.1016/j.compbiolchem.2023.107902

Breast cancer is characterized as being a heterogeneous pathology with a broad phenotype variability. Breast cancer subtypes have been developed in order to capture some of this heterogeneity. Each of these breast cancer subtypes, in turns retains varied characteristic features impacting diagnostic, prognostic and therapeutics. Basal breast tumors, in particular have been challenging in these regards. Basal breast cancer is often more aggressive, of rapid evolution and no tailor-made targeted therapies are available yet to treat it. Arguably, epigenetic variability is behind some of these intricacies. It is possible to further classify basal breast tumor in groups based on their non-coding transcriptome and methylome profiles. It is expected that these groups will have differences in survival as well as in sensitivity to certain classes of drugs. With this in mind, we implemented a computational learning approach to infer different subpopulations of basal breast cancer (from TCGA multi-omic data) based on their epigenetic signatures. Such epigenomic signatures were associated with different survival profiles; we then identified their associated gene co-expression network structure, extracted a signature based on modules within these networks, and use these signatures to find and prioritize drugs (in the LINCS dataset) that may be used to target these types of cancer. In this way we are introducing the analytical workflow for an epigenomic signature-based drug repurposing structure. [Display omitted]